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Abstract: Recent years have seen a rapid increase in the use of gut microbiota-targeting interventions,
such as probiotics, for the treatment of psychiatric disorders. The objective of this update review was
to evaluate all randomised controlled clinical trial evidence on the efficacy of probiotics for clinical
depression. Cochrane guidelines for updated reviews were followed. By searching PubMed and Web
of Science databases, we identified 546 new records since our previous review. A total of seven studies
met selection criteria, capturing 404 people with depression. A random effects meta-analysis using
treatment type (stand-alone vs. adjunctive) as subgroup was performed. The results demonstrated
that probiotics are effective in reducing depressive symptoms when administered in addition to
antidepressants (SMD = 0.83, 95%CI 0.49–1.17), however, they do not seem to offer significant benefits
when used as stand-alone treatment (SMD = −0.02, 95%CI −0.34–0.30). Potential mechanisms of
action may be via increases in brain-derived neurotrophic factor (BDNF) and decreases in C-reactive
protein (CRP), although limited evidence is available at present. This review offers stronger evidence
to support the clinical use of probiotics in depressed populations and provides an insight into the
mode of administration more likely to yield antidepressant effects.
Keywords: depression; probiotics; systematic review; meta-analysis
1. Introduction
Major depressive disorder (MDD) is a common, complex, and heterogeneous illness
that is characterized by persistent low mood and anhedonia, and a combination of sleep
disturbances, changes in appetite, feelings of worthlessness or guilt, poor concentration,
and suicidal ideation [1]. MDD significantly diminishes quality of life [2], and is currently
the leading cause of disability worldwide [3]. It is estimated that more than 264 million
people suffer from MDD globally, and there are approximately 800,000 suicide deaths
yearly linked to depression [3].
It has been estimated that up to 60% of patients with MDD experience some degree of
non-response to the wide range of pharmacological treatments [4], which predominantly
target monoamine dysregulation in the brain. This suggests that there are other mecha-
nisms implicated in the aetiology of depression, and abnormalities in the neuroendocrine,
immune, neurotrophic, and metabolic systems have been identified [5]. Most recently,
due to advances in metagenomic technologies, the gut microbiota has also been impli-
cated in the pathophysiology of depression, via its complex bidirectional communication
with the brain, also known as the gut–brain axis [6]. Gut dysbiosis (bacterial imbalance)
and compositional differences have been identified in people with affective disorders,
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compared to healthy individuals, and these abnormalities have been linked to symptom
severity [7–10], increases in pro-inflammatory cytokines and cortisol, and decreased in
levels of brain-derived neurotrophic factor (BDNF) [11–14], among other factors, which are
prominent biomarkers of depression. Consequently, there has been a surge in novel treat-
ment paradigms targeting the gut microbiota in depressive disorders, including probiotics,
prebiotics, nutraceuticals, and various dietary interventions.
Previously, we published a systematic review of randomised controlled trials (RCTs)
testing the efficacy of probiotics for clinical depression [1]. We concluded that there was
limited evidence to substantiate health claims in clinically depressed populations, due to
the small number of high-quality studies at the time, although we tentatively suggested
there may be a beneficial effect of probiotics on depressive symptoms when administered
in addition to antidepressants. Similarly, an evaluation of potential mechanisms of action
of probiotics was deemed premature. Due to the inconclusive findings of this review,
and the numerous original articles published since in this rapidly developing field of
research, an updated review is warranted. Further, other reviews that have been pub-
lished have reported on the antidepressant properties of probiotics in a mixture of healthy
populations, populations under stress, and populations with other primary psychiatric
or non-psychiatric diagnoses (e.g., bowel disorders, fibromyalgia, neurodegenerative dis-
orders, etc.) [15–17]. However, for probiotics to be considered a viable treatment option
for depression, RCT evidence from clinically defined populations with depression rather
than with other primary diagnoses is needed. The objective of this review was, therefore,
to identify and evaluate all current evidence from RCTs on the efficacy of probiotics in
reducing depressive symptoms among people with clinical depression.
2. Materials and Methods
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) [18] guidelines, as well as guidance on performing updated reviews [19,20].
2.1. Search Details
We replicated the search strategy used in our earlier review [1]. The search was
conducted in PubMed and Web of Science on 15 May 2020. The terms searched were:
[probiotic* OR synbiotic* OR Lactobacillus OR Bifidobacterium] AND [depress* OR depres-
sion OR MDD or TRD] (all fields). The date of publication was limited from 11 April 2018
(exactly one month before the date of our previous search, to account for any potential
missed records due to a delay in appearing on databases). The search was limited to hu-
man studies (database permitting) and English language. An additional search on Google
Scholar was performed to identify any studies that may have been missed. This was further
supplemented by reviewing the bibliographies of included studies and recent reviews.
2.2. Selection Criteria
Studies were considered eligible if (1) they were RCTs, in which probiotics were
administered as the sole active intervention; (2) the effects of probiotics on depressive
symptoms were assessed as the primary outcome using a validated measure; and (3) the
presence of depression was ascertained either with a diagnostic interview or with the use
of a validated scale. RCTs in which the population was selected for the presence of another
primary condition (e.g., irritable bowel syndrome, obesity, migraine etc.) were not eligible
for inclusion.
2.3. Data Extraction
For each RCT, we extracted study (author, year, country) and population (sample
size, age, gender, method used to identify depression) characteristics. We also extracted
information on trial design, intervention content, duration, tolerability and compliance,
primary outcome measure, and any biomarkers assessed (e.g., inflammatory cytokines,
BDNF, cortisol, etc.). Continuous data describing antidepressant treatment effect were
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obtained (i.e., pre- and post-treatment depression scores or change in depression score)
and presented as standardised mean difference (Hedge’s g). Studies were also verified
against their original entries on trial registries (where available) to evaluate completeness
of reporting. Where post-hoc analyses were published, relevant data were extracted from
these as well.
2.4. Quality Assessment
Included trials were assessed for risk of bias (RoB), using an adapted version of the
Scottish Intercollegiate Guidelines Network (SIGN) tool, as previously described else-
where [21]. Studies were evaluated on nine factors, including appropriateness of the
research question, randomisation, concealment of allocation, blinding, comparability of
groups at baseline, groups treated the same throughout (includes inter-site differences),
use of standardised outcome measures, use of intent-to-treat analysis, and presence of
for-profit bias (allegiance). Overall risk of bias was rated as low, moderate, or high.
2.5. Quantitative Synthesis
We performed a random-effects meta-analysis on Hedge’s g standardised mean dif-
ference (SMD) as the effect measure, applying the inverse-variance method. Analyses
were performed using the meta package in R (version 4.0.0; R Foundation for Statistical
Computing, Vienna, Austria). Standard deviations (SDs) for mean change were extracted
where possible or extrapolated from standard error (95% confidence intervals or p-values).
Inter-study heterogeneity was quantified using the DerSimonian–Laird estimator, and is
reported with the I2 statistic, which represents the fraction of variation between studies
attributable to heterogeneity. According to convention, a value around 25% indicates low
heterogeneity, 50% is moderate, and 75% is high [22]. A significant p-value (<0.05) indicates
the presence of heterogeneity. Effect size was categorized as small (SMD = 0.2), moderate
(SMD = 0.5), or large (SMD = 0.8) [23].
Pre-planned subgroup analyses, derived from the insights of our earlier review, were
performed to explore the effects of probiotics on depressive symptoms according to treat-
ment method (i.e., add-on vs. stand-alone). Due to the low number of studies, and in
accordance with published recommendations [24], we did not perform additional sensitiv-
ity analyses, meta-regression, or assessment of publication bias. However, publication bias
was likely to have been low, as there were several studies reporting negative findings.
3. Results
3.1. Search Results
Our search identified 546 records, of which 200 were duplicates, leaving 346 uniquepub-
lications. Of these, 328 were excluded as irrelevant upon review of the title/abstract. The
full text of the remaining 18 was screened for eligibility, and 14 further articles were ex-
cluded (see Figure 1 for breakdown of reasons for exclusion). Four unique RCTs met
selection criteria. These were combined with the three RCTs included in our previous
review for the purposes of qualitative and quantitative synthesis.
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) study flow diagram for up-
dated reviews. Adapted from Stovold et al. [25]. 
3.2. Characteristics of Included Studies 
Key characteristics of the seven studies are presented in Table 1. Overall, the seven 
RCTs captured 404 people with clinical depression from five countries (Iran, Poland, Ja-
pan, New Zealand, and Australia) who were randomised in a parallel group design to 
either probiotic/synbiotic or placebo/treatment as usual (TAU). The average age was sim-
ilar across studies (35–43 years), with larger variation in gender distribution (52–85% fe-
male). The duration of the probiotic intervention was also similar: 8 weeks in six studies 
and 6 weeks in one study [26]. In terms of contents, all studies but one [27], used species 
from the Lactobacilli and Bifidobacteria genera; however, the species, strains, and dosage 
varied between studies. A key difference was the intervention mode chosen: two trials 
initiated probiotics in antidepressant-free populations, while the remaining five initiated 
probiotics in addition to antidepressants. Among these, participants in three studies were 
on stable medication and dosage for 4+ weeks prior to enrollment [27–29]; participants in 
one study had the antidepressant (fluoxetine) initiated as part of the study 4 weeks prior 
to starting on the probiotic [26]; and in one study, there was a mixture of both ongoing 
and newly initiated selective serotonin reuptake inhibitor (SSRI), although intervention 
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) study
flow diagram for updated reviews. Adapted from Stovold et al. [25].
3.2. Characteristics of Included Studies
Key characteristics of the seven studies are pres nted in Table 1. Overall, the seven
RCTs captured 404 people with clinical depression from five countries (Iran, Poland, Japan,
New Zealand, nd Australia) who were randomised in a parall l group ign to either
probiotic/synbiotic or placebo/treatment as usual (TAU). The average age was similar
across studies (35–43 years), with larger variation in gender distribution (52–85% female).
The duration of the rob otic int rvention was also similar: 8 weeks in six studies and
6 weeks in one study [26]. In terms of contents, all studies but one [27], used species
from the Lactobacilli and Bifidobacteria genera; however, the species, strains, and dosage
varied between studies. A key difference was the intervention mode chosen: two trials
initiated probiotics in antidepressant-free populations, while the remaining five initiated
probiotics in addition to antidepressants. Among these, participants in three studies were
on stable medication and dosage for 4+ weeks prior to enrollment [27–29]; participants in
one study had the antidepressant (fluoxetine) initiated as part of the study 4 weeks prior
to starting on the probiotic [26]; and in one study, there was a mixture of both ongoing
and newly initiated selective serotonin reuptake inhibitor (SSRI), although intervention
groups did not differ on this parameter [30]. Studies also varied in terms of depression
severity, ranging from mild/moderate to treatment-resistant. All studies used validated
scales as the primary outcome measure, with four studies employing a self-rated measure
(Beck Depression Inventory, BDI) and the remaining three employing a clinician-rated
measure (Hamilton Depression Rating Scale (HAMD) or Montgomery–Asberg Depression
Rating Scale (MADRS)). These three scales are the most widely used in the field, and their
reliability and comparability are well described [31,32].
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3.3. Quality Assessment
Overall, study quality was high, as six studies were rated as having low RoB and
only one was rated as having high RoB [27]. This study raised multiple concerns, as it
was an open-label study with an undescribed method of randomisation and probable
commercial conflict of interest. We performed the meta-analysis with and without this
study to evaluate its impact on our results. Issues raised in the remaining studies pertained
to uncertainty regarding the similarity of groups as a baseline (two studies), and not using
an intent-to-treat analysis approach (one study). The full quality assessment is available
online as Table S1.
3.4. Efficacy of Probiotics for the Treatment of Depressive Symptoms
Overall, there was a positive effect of probiotics on depressive symptoms (SMD = 0.58,
95% CI = 0.19–0.97), with high and significant heterogeneity (I2 = 73%, p < 0.01).
When we investigated the efficacy of probiotics according to treatment type (add-on vs.
stand-alone), the analysis demonstrated that probiotics significantly reduce depressive symp-
toms when administered in addition to antidepressants (SMD = 0.83, 95% CI = 0.49–1.17),
but not when administered as stand-alone treatment (SMD = −0.02, 95% CI = 0.34–0.30)
(Figure 2). Further, this sub-group analysis according to treatment type reduced hetero-



























Figure 2. Forest plot of reduction in depressive symptoms post-treatment, grouped by treatment type (adjunctive vs.
stand-alone).
We then removed the Miyaoka et al.’s [27] data from the analysis, to explore the individ-
ual impact of this study, which was highlighted as having a high RoB. The result remained
significant, with a reduction in the size of the effect (SMD = 0.67, 95% CI = 0.40–0.95). There-
fore, our findings indicate at least a moderate effect of probiotics in alleviating depressive
symptoms when used as adjunctive treatment to an antidepressant.
3.5. Probiotics and Biomarkers of Depression
The effects of probiotics on known biomarkers of depression were assessed in five
studies. The range of parameters evaluated was wide, and included inflammatory markers,
BDNF, cortisol, kynurenine and tryptophan levels and associated ratios, metabolic markers,
oxidative stress markers, vitamin D, leptin, and gut microbiota markers. Among those
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investigated in more than one study, pro-inflammatory cytokines interleukin (IL)-6 and
tumor necrosis factor alpha (TNF-α) showed no significant differences between probiotic
and placebo-treated participants post-intervention, while IL-1β was significantly reduced
in one study [35]. However, this became non-significant after controlling for body mass
index (BMI) and dietary intake. C-reactive protein (CRP) was significantly reduced in
the probiotic arm (compared to placebo) in a study that applied probiotics as adjunctive
therapy [28], but not in a study of medication-free participants [33]. Similarly, BDNF
was found to be significantly increased following probiotic treatment only when this was
applied as adjunctive [36], and not as stand-alone treatment [33]. Interestingly, an inverse
correlation between increases in BDNF and depression severity were also reported in
this study [36]. The tryptophane/kynurenine ratio was measured in two add-on studies,
but only found to significantly differ in one, with a reduction in the probiotic arm [29].
Finally, two add-on studies assessed cortisol (urinary vs. plasma) and reported statistically
non-significant differences. However, Kazemi et al. observed a reduction of 20% in the
probiotic group (compared to no reduction in the placebo group), which they argued may be
clinically significant [35]. The remaining results are summarized in Table 2. Meta-analyses
were not performed, due to the small number of observations per parameter.
Table 2. Biomarkers assessed in the included studies and corresponding findings (most frequently measured first).
Parameter Assessed Study Outcome
Inflammatory markers
(IL-1β, IL-6, TNF-α)
Romijn (2017) [33] No significant differences.
Kazemi (2019) [35] No significant differences after adjustment formultiple covariates.
Rudzki (2019) [30] No significant differences.
CRP
Akkasheh (2015) [28] Significantly reduced in the probiotic groupcompared to placebo post-treatment.
Romijn (2017) [33] No significant difference.
BDNF
Romijn (2017) [33] No significant difference.
Kazemi (2019) [36]
Significantly increased in the probiotic group
compared to placebo post-treatment. This was
significantly correlated with reduction in
depressive scores.
Tryptophane/kynurenine ratio Kazemi (2019) [29]
Tryptophan/kynurenine ratio significantly
reduced in the probiotic group compared to
placebo post-treatment.




Not statistically significant, but potentially
clinically relevant reduction in the probiotic
group compared to placebo post-treatment
Rudzki (2019) [30] No significant difference.
Metabolic markers (insulin, FPG,
lipids, cholesterol) Akkasheh (2015) [28]
Serum insulin and insulin resistance were
significantly reduced in the probiotic group
compared to the placebo group post-treatment.
Oxidative stress
(tac, gsh) Akkasheh (2015) [28]
GSH levels significantly increased in the
probiotic group compared to the placebo group
post-treatment.
Kynurenine Rudzki (2019) [30]
Kynurenine significantly decreased in the
probiotic group compared to the placebo group
post-treatment.
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Table 2. Cont.
Parameter Assessed Study Outcome
Tryptophan Rudzki (2019) [30] No significant difference.
Other kynurenine ratios Rudzki (2019) [30]
3HKYN/KYN ratio significantly decreased in
the probiotic group compared to the placebo
group post-treatment.
Other tryptophan ratios Kazemi (2019) [29]
Tryptophan/isoleucine ratio significantly
reduced in the probiotic group compared to the
placebo group post-treatment.
Leptin Kazemi (2019) [37] No significant difference (p = 0.07).
Vitamin D Romijn (2017) [33] No significant difference.
Gut microbiota
(diversity and abundance) Chahwan (2019) [34] No significant differences.
IL: interleukin, TNF-α: tumour necrosis factor alpha, CRP: C-reactive protein, BDNF: brain-derived neurotrophic factor, FPG: fasting
plasma glucose, TAC: total antioxidant capacity, GSH: glutathione.
3.6. Tolerability and Compliance
Table 3 provides a breakdown of adherence, drop-out, and adverse event data from the
seven trials. Overall, probiotics were well-tolerated, with no serious adverse events in any
study. One study did not report adverse event (AE) data [28], while the remaining six RCTs
stated that all AEs recorded were mild, transient, and did not lead to trial discontinuation.
The most frequently reported side-effects were gastrointestinal, including bloating, nausea,
constipation, diarrhoea, and cramps. Also reported in more than one study were changes
in appetite, dry mouth, and headache. Attrition rates were similar between the treatment
and control groups in all studies. However, two studies (Chahwan et al. and Kazemi et al.)
reported a high drop-out rate of nearly 30%, which was attributed to burdensome visit
frequency in one of the studies. Regarding adherence, 5/7 studies explicitly stated this was
monitored, but only three reported actual data.
Table 3. Drop-out, tolerability, and compliance rates in the included studies.
Study
Drop-Out Rate (n/Total n) Adherence %
(Doses Taken)
Adverse Events n *
Probiotic Control Probiotic Control
Akkasheh (2015) [28] 3/20 2/20 90% nr nr
Romijn (2017) [33] 7/40 3/39 97% 77 91
Kazemi (2019) [29] 10/38 10/36 92% 10 1
Ghorbani (2018) [26] 0/20 0/20 Not mentioned 13 3
Miyaoka (2018) [27] 0/20 0/20 Not mentioned 3 3
Rudzki (2019) [30] 10/40 9/39 Monitored, nr 5 7
Chahwan (2019) [34] 11/34 13/37 Monitored, nr 65 43
* No serious adverse events (AEs) were reported in any study. High numbers in some studies reflect use of different methodology for
collecting AE data (e.g. checklist). nr = not reported.
4. Discussion
In this review, we aimed to evaluate all up-to-date evidence from RCTs on the effi-
cacy of probiotics as a treatment for depressive symptoms among people with clinical
depression without another primary diagnosis. Our analysis of the seven identified trials,
capturing just over 400 depressed individuals, demonstrated that probiotics significantly
reduce depressive symptoms after eight weeks of use, but only when used in addition to
an approved antidepressant. The current limited evidence does not support the use of
probiotics as a stand-alone treatment for depression.
At present, it is challenging to explain why probiotics may be effective as adjunctive
therapy only. Largely, this is due to our poor understanding of the impact of antidepres-
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sants themselves on the gut microbiota. Here, we discuss two potential explanations:
synergistic effect and additive effect. Studies have now established that antidepressants
from most classes (including SSRIs, SNRIs, tricyclic antidepressants (TCA), monoamine
oxidase inhibitors (MAOI), atypical and NMDA receptor antagonists) exhibit antimicrobial
activity; however, the nature of this activity may differ between classes [38]. Conversely,
some antibiotics also present antidepressant properties, and their efficacy for treatment-
resistant depression is currently under investigation (e.g., minocycline [39,40]). It is yet
unclear how the compositional gut microbiota abnormalities identified in depression [7,8]
are impacted by these treatments. However, the long-term use of antidepressants with
antimicrobial properties (which is commonly the case) likely leads to the development of
adaptive alterations in the microbiota [38]. It is yet unclear whether this is to be considered
an adverse effect or a mechanism of antidepressant action in the gut [38]. For example,
chronic use of certain antidepressants with antimicrobial properties has been linked to
microbial resistance [41], as depressed adults taking these medications seem to be more
likely to develop C. difficile infections [42], and might also explain some commonly re-
ported gastrointestinal side-effects and comorbidities (e.g., irritable bowel syndrome (IBS).
Additionally, Flowers et al. [43] found that in adults with bipolar disorder atypical antipsy-
chotics significantly decreased bacterial species known to have beneficial anti-inflammatory
properties. Maintenance of a neuroinflammatory state in psychiatric disorders has previ-
ously been linked to gut dysbiosis [13]. Therefore, probiotics may exert their therapeutic
benefits by restoring microbial balance in the gut, and also by minimising gastrointestinal
complaints in these patients, allowing for the effects of antidepressant medication to not
be dampened. On the other hand, it has also been proposed that antidepressants may
themselves exhibit some restorative effects to the gut microbiota, impacted by prolonged or
severe depressive illness [41], and that their antimicrobial effects differentially affect genera
that are commonly correlated with human health and dysbiosis [38], thus providing an im-
proved opportunity for probiotic supplements to exert their beneficial effects. For example,
a recent study in rats found that the NMDA receptor antagonist ketamine amplifies levels
of the genus Lactobacilli [44], which has been found to be reduced in depressed animals,
with some evidence of decreases in clinical populations as well [45,46]. Further studies are
needed to understand the possible synergistic interaction of probiotics and antidepressants
in depression.
Alternatively, it has been proposed that probiotics may be effective for subtypes or
symptoms of depression where conventional antidepressants have limited efficacy. For
example, SSRIs have been found to be less effective for the treatment of anhedonia [47,48]
and somatic presentations [49], while both SSRIs and SNRIs have shown limited efficacy
for cognitive impairment [47,50] and anxious depression [51]. Simultaneously, animal
models have identified various probiotics from the Lactobacilli and Bifidobacteria genera
to be effective against each of these symptoms/sub-types (for a recent review, see [52]).
Indeed, one of the RCTs included in this review, which applied a multi-strain probiotic
as stand-alone treatment, reported significantly reduced cognitive reactivity to a sad
mood, while overall depression was not improved [34]. This suggests probiotics may
have an additive effect, by positively impacting symptoms that typical antidepressants
are less effective against. However, not all commonly used depression rating scales assess
these symptoms (e.g., the Patient Health Questionnaire (PHQ-9), Hospital Anxiety and
Depression Scale (HADS)), and even those that include some items evaluating these
symptoms (e.g., MADRS, HAMD-17, BDI), have been criticised for lack of sensitivity
towards atypical presentations [53], as they do not cover the full range of symptoms and
measure only unilateral change (e.g., decreased sleep, decreased appetite). Therefore, the
selection of outcome measures that cover the full range of depressive symptoms may be
most appropriate in this field of research.
Nevertheless, our finding is inconsistent with a plethora of pre-clinical findings, where
probiotics have exhibited antidepressant properties in the absence of another treatment [11].
This translational gap may be due to the larger complexity and inter-personal variation
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in the gut microbiota in humans, and its susceptibility to influences from a wide range
of factors, many of which cannot be controlled within clinical trials. A further source of
variance stems from the wide array of symptoms and presentations covered under the
umbrella term “depression”.
Despite the limited overlap between current clinical trials, two potential candidate
mechanisms of action of probiotics as adjunctive therapy may be emerging from present
evidence: an increase in BDNF and decrease in CRP levels. Significant differences for these
biomarkers were reported in the probiotic group post-intervention only in studies with
medicated participants. Attenuations in serum levels of the growth factor BDNF have been
linked to depression, and importantly, to antidepressant response [5]. Indeed, the study
that found a significant increase of BDNF in the probiotic group compared to the placebo
group also reported a significant correlation between increases in BDNF and BDI score re-
duction [36]. Both RCTs that measured BDNF used the same probiotic strains (L. helveticus
+ B. longum), which have previously been linked to BDNF increases in a mouse model
of depression [14]. Other probiotic formulations have also been found to increase hip-
pocampal BDNF in mice [12,54,55]. CRP is a marker of chronic inflammation that appears
frequently and reliably elevated in depressed populations [5]. A study of antidepressant
non-responders reported that CRP was elevated in nearly half the population [56]. This
suggests that probiotics may be contributing to the antidepressant response by reducing
levels of CRP. Multiple animal and healthy volunteer studies have demonstrated that
probiotics and the gut microbiota can alter circulating levels of pro-inflammatory and
anti-inflammatory cytokines [13]. However, no significant changes in other inflammatory
markers were detected in any of the RCTs. Unfortunately, the included studies did not
report depression subtype, and inflammatory profiles are suggested to differ between
subtypes [57]. Thus, further studies are needed to evaluate the anti-inflammatory potential
of probiotics in clinical depression. Other mechanisms of action explored were metabolic
markers, cortisol, markers of oxidative stress, and tryptophan metabolism; however, the
evidence for these was either inconclusive or limited (i.e., measured only in one study).
An important objective for future research is to understand the impact of probiotics on
key biomarkers of depression in clinical populations, as well as the relationship with
treatment response.
In terms of optimal probiotic supplement content and dosage, there is little consensus
at present, as reflected by the trials captured in this review. As extensively discussed
elsewhere, different probiotics may be more beneficial for certain depressive symptoms or
subtypes [52]; however, RCTs in depression usually do not report symptom-level data, thus
making it difficult to establish strain-specific effects in clinical populations. While efforts
to delineate the contributions and function of individual probiotics in single-strain, pre-
clinical studies have been made, multistrain formulations have shown higher potency in
humans, and are suggested to exhibit synergistic effects, with an expanded benefit on host
physiology [52]. Therefore, a reasonable and simultaneously cost-effective strategy seems
to be the use of a multi-strain probiotic. Nevertheless, the selection of intervention contents
needs to be evidence-based. Finally, while probiotics seem to be very well tolerated in the
short term, the long-term safety and efficacy of these interventions remains to be evaluated,
along with an appropriate follow-up to assess relapse rates.
One limitation of this review was the small number of studies included. While other re-
views have captured larger numbers of studies, these have also included healthy volunteers
and populations with a primary condition other than depression, as well as no restrictions
on trial design. We considered this approach to be of limited value in determining the
clinical utility of probiotics for the treatment of depression, and therefore restricted our
inclusion criteria to only capture RCT designs and populations meeting a clinical cut-off
for depression with no other primary diagnosis. This limited the power of our analyses,
but increased specificity. While our sub-group analysis on the basis of treatment mode
(stand-alone vs. add-on) yielded a clear reduction in heterogeneity and rendered it non-
significant, it remains possible that there were other sources of similarity between the two
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stand-alone studies that were unknown to the authors, and could provide an alternative
explanation to our findings. This meta-analysis should be updated whenever sufficient
new data become available. Another limitation stemming from the small number of studies
was the inability to perform meta-analyses of potential mechanisms of action. Next, while
we included only clinically depressed populations, the definition of depression we adopted
was broad (i.e. beyond diagnosis based solely on a structured clinical review). This was
deemed acceptable here, as clinically recognized cut-offs on validated depression scales
were employed by studies and significant comorbidities were screened out. Nevertheless,
higher clinical heterogeneity may have been present in studies employing this method
of recruitment.
5. Conclusions
Our updated analysis demonstrates that probiotics are effective in reducing depressive
symptoms when administered in addition to antidepressants; however, they do not seem to
confer significant benefits when used as stand-alone treatment. The evidence summarized
here supports the clinical use of probiotics in depressed populations and provides an insight
into the mode of administration more likely to yield antidepressant effects. However,
little remains known about the mechanisms underlying the antidepressant properties of
probiotics and their interaction with antidepressants in clinically depressed populations.
Further large efficacy trials simultaneously assessing the impact of probiotics on known
biomarkers of depression are needed.
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